Sorted by Relevance | Sort by Date
Search Results for diabetes
Government diabetes study hits a speed bump
The National Institutes for Health has announced the partial suspension of a diabetes treatment study which was focusing on aggressive measures to reduce blood sugar levels. An article in The Wall Street Journal indicates that the aggressive strategy ...
Novartis (NVS) sees progress on diabetes drug
Novartis AG (NYSE: NVS) shares are trading higher today after the company reported progress with Galvus, a drug the company is developing to treat type-2 diabetes. Shares are up slightly on this news even as another drug being developed by NVS and ...
Amylin (AMLN): 'Blockbuster potential' in diabetes
"After its run to a new all-time high last month, Amylin (NASDAQ: AMLN) appears to be undergoing some upper level consolidation," notes biotech specialist John McCamant.
Following a presentation by the firm's CEO at a biotech conference, the editor ...
Drinking coffee may make diabetes worse?
I drink a lot of coffee. Is it good for me? Nah. And when I get a throbbing headache from it, sometimes there's nothing better to do than just feed the monster and drink more. So, yeah, I drink too much coffee but what's a father of five supposed to ...
Eli Lilly to restructure, bet on drug portfolio
Pharmaceutical company Eli Lilly & Co. (NYSE: LLY) is planning to cut 5,500 jobs over the next few years and reorganize into five business units. The company is looking to reduce costs and accelerate how long it takes new drugs to get to ...
Cramer's diabetes & specialty metals stocks
On tonight's MAD MONEY on CNBC, Jim Cramer said the bulls got what they wanted as the Federal Reserve is removing the "firming" bias from their statement today. The market is back, according to Cramer. The defensive stocks bottomed, then the ...
Top 25 stocks for the NEXT 25 years: DexCom
The NEXT company in my on-going series of the top 25 stocks for the NEXT 25 years is DexCom, Inc (NASDAQ: DXCM). This San Diego, California-based company has the opportunity to address the millions of people that suffer from diabetes. DexCom ...
Top 25 Stocks for the NEXT 25 years: DexCom (DXCM) update
Back on June 13, I wrote about DexCom Corp. (NASDAQ: DXCM) as one of the top 25 stocks for the NEXT 25 years. The stock was just under $7 with a market capitalization of $180 million. Today the stock is at $9.61 with a market cap of $280 million. The ...
Today in Money & Finance - 6/1 - The Butler Boom, High Cost of Diabetes Debate & Ultra-Mobile PC
In the News:
· KFC Japan Finds Glass, Pulls Cabbage
· Woman Sues eHarmony for Discrimination
· Hovnanian Posts Third Straight Loss
· RadioShack Controller to Leave
· The Bancrofts to Meet With Murdoch re: Dow ...
Splenda vs. Equal: Battle of the Brands
This post is part of our Battle of the Brands feature. Let us know which brand you prefer, and check out other Battle of the Brands posts.
I never paid that much attention to the pink and yellow and blue packets on the table when my wife and I go out ...
Medtronic increases adjusted income, beats by a penny
Medtronic (NYSE: MDT), a manufacturer of a whole host of medical devices involved with the management of diabetes and cardiovascular disease, released its Q1 data on Tuesday. Revenues increased 6%, and adjusted earnings per share came in at 79 cents ...
Please don't tax Coke!
As a Coca-Cola (NYSE: KO) shareholder, I was quite unnerved by recent talk centering on the issue of a soda tax. I'm sure PepsiCo (NYSE: PEP) shareholders were likewise frightened. According to Bloomberg, President Barack Obama is apparently open to ...
Biotech expert: A love affair with Amylin (AMLN)
"Right now I'm having a love affair with Amylin Pharmaceuticals Inc. (NASDAQ: AMLN); frankly, you should be in love with it, too." says Michael Shulman, editor of the industry-leading ChangeWave Biotech Investor.
The advisor notes, "Not only is it ...
Cramer on BloggingStocks: Sanofi has lots of upside catalysts
From TheStreet.com Network
Dollar Store: Early Volume Plays
Dollar Could Steer Stocks in Coming Week
TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all. Now that we see that health care reform is ...
MannKind: Speculation on inhaled insulin
"In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile.
In his growth-oriented Nate's Notes, the advisor cautions, "I ...
Google's plan for netbook PCs moves higher into the clouds
Closing Bell: Stock bulls and dollar death (DDRX,GMCR, PEET, SBUX, EBAY, CI, TECD)
So long peak oil, here comes peak uranium
